83 related articles for article (PubMed ID: 29191581)
21. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
[TBL] [Abstract][Full Text] [Related]
22. Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.
Li A; Niu FY; Han JF; Lou NN; Yang JJ; Zhang XC; Zhou Q; Xie Z; Su J; Zhao N; Huang Y; Wu YL
Lung Cancer; 2015 Dec; 90(3):375-80. PubMed ID: 26791795
[TBL] [Abstract][Full Text] [Related]
23. Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
Lee SH; Choi SI; Lee JS; Kim CH; Jung WJ; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Cancer Res Treat; 2017 Jan; 49(1):141-149. PubMed ID: 27188201
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
Ma K; Xu W; Wang C; Li B; Su K; Li W
Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
[TBL] [Abstract][Full Text] [Related]
25. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
[TBL] [Abstract][Full Text] [Related]
26. Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients.
Dacosta-Noble P; Costantini A; Dumenil C; Dumoulin J; Helly de Tauriers P; Giraud V; Labrune S; Emile JF; Alvarez JC; Chinet T; Giroux Leprieur E
PLoS One; 2019; 14(7):e0219080. PubMed ID: 31260495
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
[TBL] [Abstract][Full Text] [Related]
28. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
31. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
[TBL] [Abstract][Full Text] [Related]
32. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.
He YY; Zhang XC; Yang JJ; Niu FY; Zeng Z; Yan HH; Xu CR; Guan JL; Zhong WZ; Yang LL; Guo LH; Wu YL
Clin Lung Cancer; 2014 Nov; 15(6):441-7. PubMed ID: 25044104
[TBL] [Abstract][Full Text] [Related]
34. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
35. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
36. The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study.
Dediu M; Crisan E; Radut M; Tarlea A; Median D; Alexandru A; Vremes G; Gal C
Lung Cancer; 2009 Feb; 63(2):271-6. PubMed ID: 18565617
[TBL] [Abstract][Full Text] [Related]
37. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
Tong KM; Laskin J; Ho C
Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
[TBL] [Abstract][Full Text] [Related]
38. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
Wang Z; Yang H; Luo S; Liu B; Zhang N; Li L; Zhou S; Shen R; Xie X
Lung Cancer; 2017 Oct; 112():1-9. PubMed ID: 29191580
[TBL] [Abstract][Full Text] [Related]
40. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
